點擊視頻觀看
??????
責任編輯:覓健蘇蘇
文中圖片來源已經(jīng)授權
參考來源:
1. Arnold M, Morgan E, Rumgay H et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 2022; 66: 15–23.
2. Johnston SRD, Harbeck N, Hegg R et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR , HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38: 3987–3998.
3. Si W, Li Y, Han Y et al. Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013: A Retrospective Study. Medicine (Baltimore) 2015; 94: e820.
4. Allemani C, Matsuda T, Di Carlo V et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet 2018; 391: 1023–1075.
5. Sheffield KM, Peachey JR, Method M et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol 2022; 18: 2667–2682.
聯(lián)系客服